GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (NAS:PRTA) » Definitions » Cyclically Adjusted PS Ratio

Prothena (Prothena) Cyclically Adjusted PS Ratio : 19.26 (As of Apr. 30, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Prothena Cyclically Adjusted PS Ratio?

As of today (2024-04-30), Prothena's current share price is $21.19. Prothena's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.10. Prothena's Cyclically Adjusted PS Ratio for today is 19.26.

The historical rank and industry rank for Prothena's Cyclically Adjusted PS Ratio or its related term are showing as below:

PRTA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 18.96   Med: 53.96   Max: 157.29
Current: 18.96

During the past years, Prothena's highest Cyclically Adjusted PS Ratio was 157.29. The lowest was 18.96. And the median was 53.96.

PRTA's Cyclically Adjusted PS Ratio is ranked worse than
83% of 506 companies
in the Biotechnology industry
Industry Median: 5.395 vs PRTA: 18.96

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Prothena's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.006. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.10 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Prothena Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Prothena's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Cyclically Adjusted PS Ratio Chart

Prothena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 65.43 66.19 33.01

Prothena Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.19 52.09 71.66 43.60 33.01

Competitive Comparison of Prothena's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Prothena's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prothena's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Prothena's Cyclically Adjusted PS Ratio falls into.



Prothena Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Prothena's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=21.19/1.1
=19.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prothena's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Prothena's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.006/120.1096*120.1096
=0.006

Current CPI (Dec. 2023) = 120.1096.

Prothena Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.405 100.573 1.678
201406 0.660 100.773 0.787
201409 0.054 100.474 0.065
201412 0.073 99.576 0.088
201503 0.022 99.975 0.026
201506 0.009 100.573 0.011
201509 0.014 100.274 0.017
201512 0.010 99.676 0.012
201603 0.008 99.676 0.010
201606 0.010 101.072 0.012
201609 0.008 100.274 0.010
201612 0.005 99.676 0.006
201703 0.007 100.374 0.008
201706 0.704 100.673 0.840
201709 0.006 100.474 0.007
201712 0.006 100.075 0.007
201803 0.006 100.573 0.007
201806 0.007 101.072 0.008
201809 0.006 101.371 0.007
201812 0.005 100.773 0.006
201903 0.005 101.670 0.006
201906 0.004 102.168 0.005
201909 0.005 102.268 0.006
201912 0.006 102.068 0.007
202003 0.004 102.367 0.005
202006 0.005 101.769 0.006
202009 0.004 101.072 0.005
202012 0.009 101.072 0.011
202103 0.004 102.367 0.005
202106 1.267 103.364 1.472
202109 2.718 104.859 3.113
202112 0.022 106.653 0.025
202203 0.025 109.245 0.027
202206 0.028 112.734 0.030
202209 0.032 113.431 0.034
202212 1.019 115.425 1.060
202303 0.041 117.618 0.042
202306 0.076 119.611 0.076
202309 1.463 120.708 1.456
202312 0.006 120.110 0.006

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Prothena  (NAS:PRTA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Prothena Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Prothena's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Prothena (Prothena) Business Description

Traded in Other Exchanges
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Executives
Karin L Walker officer: See Remarks C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brandon S. Smith officer: Chief Operating Officer C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Carol D. Karp officer: Chief Regulatory Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Michael J Malecek officer: Chief Legal Officer C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hideki Garren officer: Chief Medical Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Wagner M. Zago officer: Chief Scientific Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dennis J. Selkoe director 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Tran Nguyen officer: Chief Financial Officer C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gene G. Kinney officer: CSO & Head of R&D C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dunn William H. Jr. director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Richard T Collier director
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Paula K Cobb director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453